by Zeflik | May 21, 2020 2:09 am
Does anyone could guess which `biotech/medical stock Jeff Brown[1] is promoting in the ”Penny IPO[2]`s” pitch? All of them have potential for at least 10x growth. Here is the link to the pitch https://secure.bonnerandpartners.com/?cid=MKT459805&eid=MKT463356&step=start&plcid=PLC069177&SNAID=SAC0010464081&email=jozef.szlufcik@gmail.com&encryptedSnaid=mtFugfkIjQZwvQduYvOPoJkMUqW8Rkx1t2V4kZtac6o%3D&emailjobid=4646829&emailname=20200520-TBE-F&assetId=AST136084&page=2[3]
Grtx,
Zeflik
Source URL: https://www.stockgumshoe.com/2020/05/microblog-jeff-browns-penny-ipos/
Copyright ©2024 Stock Gumshoe unless otherwise noted.
Two stocks, from previously decoded by Gumshoe community pitching of Jeff Brown, brought me quite good profit. By this I consider him a good analyst worth listening.
WHAT ARE THEY?
ANY IDEAS HERE
I have not subscribed to the ipo service but have seen the presentation. I’m also in healthcare and familiar with the fda process. I believe IPO 3 is Editas for a few reasons.
In this presentation, and a few others he’s done for other services, there are slides that appear showing FDA trial data. Trial number can be seen, and in a different video for another service, the actual company was shown. Im sure that was a mistake. But the trial numbers were the same across both.
Crisper (gene editing) is patented and only used by a handful of companies. In this presentation, in the background, one can see LCA-10 in a slide that is a bit blurry. This is Leber Congenital Amarousis (congenital blindness). By searching publicly-available trial data, the only company that comes up as having a phase 1/2, in vivo, ongoing trial for autosomal dominant LCA is Editas.
This is it: https://clinicaltrials.gov/ct2/show/NCT03872479
In other slides, current share price is shown and also fits at 20-30, currently around $27 I believe, as does it’s current market cap.
In-vivo gene editing, if successful, would be a first-in-class therapy. Editas also has a few other potential gene targets for other conditions.
I haven’t researched ipo 1 or 2 yet. Interested to hear others’ thoughts.
Yes I can confirm from my side that Editas is one from the companies according to the description. Only doubt I have is if it can be considered as a penny stock?
Agree. Early stage for sure but a penny stock it is not. But if their phase II comes through, and they are the first to cure a major genetic condition with gene editing, the sky’s the limit.
I looked into IPO #1 and think it’s kaleido (kldo). Jeff Gordon is collaborating, they have a focus on using the microbiome to treat hepatic encephalopathy (sequela of cirrhosis), partnership with Janesson, a division of J&J tasked with treating pediatric atopic (allergic) conditions, and they are a microcap in target price range with a planned phase II trial this summer.
This is my opinion only, based on the (misleadingly annotated) charts in Jeff’s presentation and cross-referencing some of the info he shares with Crunchbase: 1 – KLDO, 2 – DTIL, 3 – EDIT.
absolutely right – nailed it on all 3.
stock no 2 confirmation below.
https://www.wraltechwire.com/2020/01/15/precision-biosciences-hits-two-key-fda-milestones-in-advancing-gene-therapy-for-cancer/
i am considering subscribing, are you and actual subscriber and are you please with the service?
I am a paying irregular for several years, so yes, I am happy with it
THANKS! i have dug a little more and i am ready to take the plunge… happy trading!
How do I but stock? Where in north California do I but it. How do i buy it on the Internet?
Got Mr Browns five g play from Travis J and it is up nicely .(akts)